Introduction
HCV is a hepatotropic, lymphotropic virus affecting over 180 million people, all over the world by chronic infection. 1 In Egypt, the prevalence rate of HCV infected individuals was 872,000 (15% of the population) in 2013, with an estimated incidence of newly infected 125,000 viremic individuals each year 2 , the rate which is considered as one of the highest prevalence rates of HCV worldwide. 3 Management of HCV infection is more challenging in patients with hematologic malignancies than in patients without cancer because of a higher rate of progression of fibrosis, more rapid development of cirrhosis, increased viral titers, worse outcome, and exclusion from some cancer and/or antiviral treatments. Elimination of HCV from infected patients with hematologic malignancies has the potential for virologic, hepatic, and oncologic benefits ( Table 1 ). 4 Table (1) Benefits of HCV treatment in patients with hematologic malignancies (5) Infectious and hepatic 1. Prevention of long-term complications such as liver cirrhosis and end-stage liver disease 2. Prevention of hepatocellular carcinoma as a primary or secondary cancer in patients with chronic HCV infection 3. Improvement of long-term survival 4. Treatment of extrahepatic manifestations (cryoglobulinemia, fatigue) Oncologic 1. Allowing patients access to multiple clinical trials of cancer chemotherapies, including trials of agents with hepatic metabolism 2. Prevention of some HCV-associated hematologic malignancies (e.g. non-Hodgkin lymphoma) or decrease of the relapse rate of those malignancies 3. 3. Cure of selected HCV-associated hematologic malignancies without chemotherapy
How I treat hepatitis C virus infection in patients with hematologic malignancies
Among patients infected with HCV, those with hematologic malignancies, and especially patients who have undergone HCT, have a more rapid rate of fibrosis progression and a higher risk of developing cirrhosis than patients without cancer. Among patients with cancer, HCV screening and early diagnosis, assessment of liver fibrosis, and elimination of HCV will likely improve long-term outcomes. Groups for whom HCV screening is recommended include candidates for HCT, patients with hematologic malignancies and other cancer patients as recommended in patients without cancer. HCV screening is recommended before starting selected chemotherapy agents (e.g., rituximab, alemtuzumab) and before enrolment on clinical trials with investigational antineoplastic agents. Discovery of HCV infection in a patient newly diagnosed with a hematologic malignancy should prompt virologic tests and fibrosis assessments ( Table 2) . In general, in patients with hematologic malignancies and HCV infection, ALT level should be evaluated at baseline and periodically during chemotherapy or immunosuppressive therapy to identify unusual cases of more severe hepatocellular injury or fibrosing cholestatic hepatitis C. Routine monitoring of HCV RNA is not recommended; however, HCV RNA should be measured in all patients at entry into care, and viral load should be monitored in patients receiving HCV treatment according to standard-of-care management for patients without cancer. 4 Eradication of HCV may normalize liver function, allowing access to drugs that would otherwise be contraindicated, including agents with hepatic metabolism. SVR would prevent HCV reactivation and hepatic flare after chemotherapy, thus avoiding discontinuation or dose reduction of chemotherapy and possibly the risk of hepatic decompensation during cancer care. Longer-term benefits would include prevention of progression to cirrhosis, reduction in the risk of second primary cancers (hepatocellular carcinoma and NHL), and improved survival of patients with these secondary cancers. 10 The advent of DAAs has rendered IFN-containing regimens obsolete for treatment of HCV infection, and the benefits of DAA therapy outweigh the risks in HCV-infected patients with hematologic malignancies (Table 1) . Contraindications to treatment with DAAs in HCV infected patients with hematologic malignancies are shown in Table 3 . Table ( 3): Subgroups of HCV-infected patients with hematologic malignancies for whom DAA therapy is contraindicated. Simultaneous administration of chemotherapy and DAAs is not recommended.
However, preliminary data in a small group of cancer patients, including some with hematologic malignancies, showed that concomitant chemotherapy and DAA therapy is feasible. Because we have only limited clinical understanding of drug-drug interactions and chemotherapy tolerability in HCV-infected patients, simultaneous therapies should be used with caution. 12
HCV and lymphoma
Evidence that HCV infection may be causal in the development of lymphoma is based on several cases in which regression of lymphoma followed elimination of HCV. Most patients It is not currently known whether the high rates of HCV clearance with DAAs in the general population and in organ transplant patients can be replicated in HCT patients in the early post-HCT period, as full immune reconstitution does not occur until more than 1 year after allogeneic HCT and both immunosuppressive therapy and GVHD will delay return of immunity. Preliminary data show that DAAs are safe and effective (SVR rate, 85%) in HCVinfected HCT recipients. 22 The choice of DAA regimen should be guided by several factors (e.g., the patient's prior antiviral treatment, HCV genotype, and degree of liver disease) and should be individualized after thorough assessment for potential hematologic toxic effects and drug- 
Conclusions
HCV is now curable by DAAs in most patients, including those with hematologic malignancies. Elimination of HCV from infected patients offers potential virologic, hepatic, and oncologic benefits.
HCV infection should not contraindicate cancer therapy, and patients with chronic HCV infection and hematologic malignancies should not be excluded from clinical trials of chemotherapy or antiviral therapies. However, hepatologists and infectious diseases specialists with experience in treating HCV should participate in the diagnostic work-up, monitoring, and treatment of infected patients.
In general, the DAA combinations recommended for cancer patients mimic those used for patients without cancer. DAAs used to treat HCV in 2016 and their most common side effects are shown in table 4. The optimal therapy for HCV infected patients with cancer is evolving rapidly and will continue to evolve as new DAAs are approved and as more studies are reported.
